Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

被引：2
|
作者：
Osman, Keren [1 ]
Chari, Ajai [2 ]
Parekh, Samir [2 ]
Pun, Christine [3 ]
Morgan, Gillian [3 ]
Florendo, Erika [3 ]
Chan, Elaine [3 ]
Shields, Marisa [3 ]
Strumolo, Gina [3 ]
La, Lisa [3 ]
Mandeli, John [4 ]
Geerlof, James [5 ]
Jagannath, Sundar [2 ]
Cho, Hearn Jay [2 ]
机构：
[1] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[2] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY USA
[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[4] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA
[5] Bristol Myers Squibb, Collaborat Sci Res & Operat, Plainsboro, NJ USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3448.3448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3448
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Improvement of Response for Multiple Myeloma patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT)
    Shah, Gunjan
    Assal, Amer
    Hsu, Meier
    Devlin, Sean
    Hassoun, Hani
    Korde, Neha
    Lendvai, Nikoletta
    Lesokhin, Alexander
    Mailankody, Sham
    Smith, Eric
    Chung, David
    Koehne, Guenther
    Landgren, C. Ola
    Landau, Heather
    Giralt, Sergio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E140 - E140
  • [32] Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
    Richardson, Paul G.
    Moreau, Philippe
    Jakubowiak, Andrzej J.
    Facon, Thierry
    Jagannath, Sundar
    Vij, Ravi
    Reece, Donna E.
    White, Darrell J.
    Raab, Marc S.
    Benboubker, Lotfi
    Rossi, Jean-Francois
    Tsao, Claire
    Fry, John
    Berman, David
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2010, 116 (21) : 434 - 434
  • [33] Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation
    Wolschke, Christine
    Schonland, Stefan O.
    Hegenbart, Ute
    Stuebig, Thomas
    Heinzelmann, Marion
    Hildebrandt, York
    Lioznov, Michael
    Zander, Axel R.
    Kroeger, Nicolaus
    BLOOD, 2010, 116 (21) : 984 - 984
  • [34] Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma
    Rath, Carolyn
    Yoo, Claude
    Cheplowitz, Halle
    Lo, Mimi
    Young, Rebecca
    Guglielmo, Julie
    Saunders, Ila M.
    Banerjee, Rahul
    Young, Richard
    Kumar, Anupama
    Chung, Alfred
    Rosenberg, Aaron Seth
    Costello, Caitlin
    Fine, Jeffrey
    Wilson, Machelle
    Patel, Nimish
    Banez, Marisela Tan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1715 - 1724
  • [35] A phase 3, two-stage, randomized study of iberdomide maintenance versus lenalidomide maintenance post autologous stem cell transplantation in newly diagnosed multiple myeloma: EXCALIBER-maintenance
    Gay, Francesca
    Dimopoulos, Meletios
    Huang, Xiaojun
    Lonial, Sagar
    Ramasamy, Karthik
    Amatangelo, Michael
    Abouihia, Abdallah
    Masin, Mark
    Maniar, Hina
    Acosta, Jorge
    Maciag, Paulo
    van de Donk, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S111 - S111
  • [36] Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma
    Buadi, Francis K.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Perez, Gabriela
    Gertz, Morie A.
    Kapoor, Prashant
    Hayman, Suzanne R.
    Dingli, David
    Go, Ronald S.
    Fonder, Amie
    Hwa, Yi L.
    Hobbs, Miriam A.
    Gonsalves, Wilson I.
    Helgeson, Dania Kaehlyn
    Kourelis, Taxiarchis
    Laplant, Betsy
    Russell, Stephen J.
    Muchtar, Eli
    Warsame, Rahma M.
    Rajkumar, S. Vincent
    Kyle, Robert A.
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [37] Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma.
    Grosskreutz, CL
    Egan, R
    Scigliano, E
    Fruchtman, SM
    Isola, LM
    BLOOD, 2003, 102 (11) : 489B - 490B
  • [38] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    International Journal of Hematology, 2017, 105 : 326 - 334
  • [39] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [40] Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against
    Richardson, Paul G.
    Holstein, Sarah A.
    Schlossman, Robert L.
    Anderson, Kenneth C.
    Attal, Michel
    McCarthy, Philip L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (18) : 1975 - 1985
12345